Mary S. Bradley

1.2k total citations · 1 hit paper
10 papers, 681 citations indexed

About

Mary S. Bradley is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Mary S. Bradley has authored 10 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Physiology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Genetics. Recurrent topics in Mary S. Bradley's work include Asthma and respiratory diseases (7 papers), Respiratory and Cough-Related Research (4 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers). Mary S. Bradley is often cited by papers focused on Asthma and respiratory diseases (7 papers), Respiratory and Cough-Related Research (4 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers). Mary S. Bradley collaborates with scholars based in United States, France and Romania. Mary S. Bradley's co-authors include Abdelkader Rahmaoui, Karin Rosén, Mark D. Eisner, Janice Canvin, Oral Alpan, Carsten Bindslev‐Jensen, Marcus Maurer, Sarbjit S. Saini, Panayiotis Georgiou and Sheldon L. Spector and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Journal of Investigative Dermatology and Respiratory Research.

In The Last Decade

Mary S. Bradley

9 papers receiving 669 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

2014 307 citations Sarbjit S. Saini, Carsten Bindslev‐Jensen et al. Journal of Investigative Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary S. Bradley United States	6	365	356	208	200	196	10	681
Abdelkader Rahmaoui United States	5	345 0.9×	277 0.8×	201 1.0×	158 0.8×	193 1.0×	8	590
Pavel Novikov Russia	10	152 0.4×	53 0.1×	82 0.4×	11 0.1×	33 0.2×	77	377
Martin Plaisance Canada	4	133 0.4×	123 0.3×	149 0.7×	23 0.1×	19 0.1×	7	408
Michael Batley United Kingdom	4	317 0.9×	68 0.2×	35 0.2×	9 0.0×	60 0.3×	6	423
C Seigneuric France	6	148 0.4×	147 0.4×	90 0.4×	12 0.1×	41 0.2×	10	402
H Pellet France	8	131 0.4×	28 0.1×	59 0.3×	30 0.1×	37 0.2×	39	312
R Scorza Italy	8	60 0.2×	32 0.1×	14 0.1×	28 0.1×	207 1.1×	14	343
Dimitrios Christidis United Kingdom	6	183 0.5×	50 0.1×	66 0.3×	8 0.0×	24 0.1×	9	313
Paolo Delvino Italy	10	128 0.4×	35 0.1×	54 0.3×	13 0.1×	71 0.4×	30	328
Philip Therkildsen Denmark	10	272 0.7×	139 0.4×	73 0.4×	20 0.1×	20 0.1×	18	435

Countries citing papers authored by Mary S. Bradley

Since Specialization

Citations

This map shows the geographic impact of Mary S. Bradley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary S. Bradley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary S. Bradley more than expected).

Fields of papers citing papers by Mary S. Bradley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary S. Bradley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary S. Bradley. The network helps show where Mary S. Bradley may publish in the future.

Co-authorship network of co-authors of Mary S. Bradley

This figure shows the co-authorship network connecting the top 25 collaborators of Mary S. Bradley. A scholar is included among the top collaborators of Mary S. Bradley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary S. Bradley. Mary S. Bradley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Iribarren, Carlos, Abdelkader Rahmaoui, Aidan A. Long, et al.. (2016). Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. Journal of Allergy and Clinical Immunology. 139(5). 1489–1495.e5. 80 indexed citations

2.

Harris, Jeffrey M., Romeo Maciuca, Mary S. Bradley, et al.. (2016). A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respiratory Research. 17(1). 29–29. 73 indexed citations

3.

Long, Aidan A., Abdelkader Rahmaoui, Kenneth J. Rothman, et al.. (2014). Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. Journal of Allergy and Clinical Immunology. 134(3). 560–567.e4. 150 indexed citations

4.

Saini, Sarbjit S., Carsten Bindslev‐Jensen, Marcus Maurer, et al.. (2014). Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study. Journal of Investigative Dermatology. 135(1). 67–75. 307 indexed citations breakdown →

5.

Zazzali, James L., Karin Rosén, Mary S. Bradley, & Karina Raimundo. (2014). Angioedema and Angioedema Management From Asteria I and Asteria II: Phase III Studies To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment. Journal of Allergy and Clinical Immunology. 133(2). AB117–AB117. 1 indexed citations

6.

Eisner, Mark D., James L. Zazzali, Mary K. Miller, Mary S. Bradley, & Michael Schätz. (2012). Longitudinal Changes in Asthma Control with Omalizumab: 2-Year Interim Data from the EXCELS Study. Journal of Asthma. 49(6). 642–648. 24 indexed citations

7.

Schätz, Michael, Mark D. Eisner, James L. Zazzali, Mary S. Bradley, & Mary K. Miller. (2011). Longitudinal Impact Of Omalizumab On Asthma Control Over Two Years. A4495–A4495. 2 indexed citations

8.

Long, Aidan A., Mark D. Eisner, Mary K. Miller, et al.. (2011). Omalizumab And The Incidence Of Malignancy: Interim Results From The Excels Study. A4492–A4492.

9.

Eisner, Mark D., et al.. (2011). Omalizumab and malignancy: Interim results from the EXCELS study. 38. 3954. 4 indexed citations

10.

Long, Aidan A., James E. Fish, Abdelkader Rahmaoui, et al.. (2009). Baseline characteristics of patients enrolled in EXCELS: a cohort study. Annals of Allergy Asthma & Immunology. 103(3). 212–219. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact